Results from MIRASOL Also Show ELAHERE is the First Treatment to Demonstrate an Overall Survival Benefit in a Phase 3 Trial in Platinum-Resistant Ovarian Cancer Compared to Chemotherapy
Clinically. | June 4, 2023
- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership –
– New Data Highlight Magrolimab’s Potential to Alter the Tumor. | June 1, 2023
A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory peripheral T cell lymphoma is accepted as a poster presentationA trial in progress abstract of the. | May 11, 2023
– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase complete.